vs
Side-by-side financial comparison of Clearfield, Inc. (CLFD) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
Clearfield, Inc. is the larger business by last-quarter revenue ($34.3M vs $18.7M, roughly 1.8× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -1.8%, a 1.0% gap on every dollar of revenue. On growth, Clearfield, Inc. posted the faster year-over-year revenue change (-3.2% vs -25.7%). Clearfield, Inc. produced more free cash flow last quarter ($-2.4M vs $-15.8M). Over the past eight quarters, Clearfield, Inc.'s revenue compounded faster (-3.5% CAGR vs -15.9%).
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CLFD vs CTMX — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.3M | $18.7M |
| Net Profit | $-614.0K | $-154.0K |
| Gross Margin | 33.2% | — |
| Operating Margin | -5.3% | -6.9% |
| Net Margin | -1.8% | -0.8% |
| Revenue YoY | -3.2% | -25.7% |
| Net Profit YoY | 67.8% | 97.6% |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.3M | — | ||
| Q3 25 | $23.4M | — | ||
| Q2 25 | $49.9M | $18.7M | ||
| Q1 25 | $47.2M | $50.9M | ||
| Q4 24 | $29.7M | $38.1M | ||
| Q3 24 | $5.6M | $33.4M | ||
| Q2 24 | $48.8M | $25.1M | ||
| Q1 24 | $36.9M | $41.5M |
| Q4 25 | $-614.0K | — | ||
| Q3 25 | $-9.1M | — | ||
| Q2 25 | $1.6M | $-154.0K | ||
| Q1 25 | $1.3M | $23.5M | ||
| Q4 24 | $-1.9M | $18.9M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | $-447.0K | $-6.5M | ||
| Q1 24 | $-5.9M | $13.8M |
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
| Q4 25 | -5.3% | — | ||
| Q3 25 | 10.3% | — | ||
| Q2 25 | 3.0% | -6.9% | ||
| Q1 25 | 0.6% | 44.4% | ||
| Q4 24 | -6.9% | 46.4% | ||
| Q3 24 | — | 12.3% | ||
| Q2 24 | -4.7% | -33.7% | ||
| Q1 24 | -26.4% | 28.1% |
| Q4 25 | -1.8% | — | ||
| Q3 25 | -38.8% | — | ||
| Q2 25 | 3.2% | -0.8% | ||
| Q1 25 | 2.8% | 46.2% | ||
| Q4 24 | -6.4% | 49.6% | ||
| Q3 24 | — | 17.2% | ||
| Q2 24 | -0.9% | -26.0% | ||
| Q1 24 | -16.0% | 33.3% |
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $-0.65 | — | ||
| Q2 25 | $0.11 | — | ||
| Q1 25 | $0.09 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.4M | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $249.7M | $119.9M |
| Total Assets | $268.1M | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $96.4M | — | ||
| Q3 25 | $106.0M | — | ||
| Q2 25 | $117.2M | $49.0M | ||
| Q1 25 | $112.0M | $47.6M | ||
| Q4 24 | $113.0M | $38.1M | ||
| Q3 24 | $129.0M | $40.6M | ||
| Q2 24 | $123.8M | $43.2M | ||
| Q1 24 | $142.9M | $36.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $249.7M | — | ||
| Q3 25 | $256.2M | — | ||
| Q2 25 | $264.5M | $119.9M | ||
| Q1 25 | $265.9M | $25.0M | ||
| Q4 24 | $267.4M | $-456.0K | ||
| Q3 24 | $275.8M | $-23.5M | ||
| Q2 24 | $274.6M | $-31.2M | ||
| Q1 24 | $279.2M | $-31.7M |
| Q4 25 | $268.1M | — | ||
| Q3 25 | $306.2M | — | ||
| Q2 25 | $314.7M | $175.1M | ||
| Q1 25 | $310.9M | $98.5M | ||
| Q4 24 | $303.2M | $120.5M | ||
| Q3 24 | $315.3M | $139.0M | ||
| Q2 24 | $318.1M | $159.2M | ||
| Q1 24 | $315.4M | $184.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.4M | $-15.8M |
| Free Cash FlowOCF − Capex | $-2.4M | $-15.8M |
| FCF MarginFCF / Revenue | -7.1% | -84.6% |
| Capex IntensityCapex / Revenue | 2.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.9M | $-15.8M | ||
| Q1 25 | $3.0M | $-21.0M | ||
| Q4 24 | $7.2M | $-19.9M | ||
| Q3 24 | $22.2M | $-20.7M | ||
| Q2 24 | $4.0M | $-19.5M | ||
| Q1 24 | $-5.7M | $-26.0M |
| Q4 25 | $-2.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.5M | $-15.8M | ||
| Q1 25 | $654.0K | $-21.2M | ||
| Q4 24 | $5.1M | $-20.0M | ||
| Q3 24 | $18.2M | $-20.7M | ||
| Q2 24 | $2.8M | $-19.6M | ||
| Q1 24 | $-7.7M | $-26.2M |
| Q4 25 | -7.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 15.1% | -84.6% | ||
| Q1 25 | 1.4% | -41.6% | ||
| Q4 24 | 17.1% | -52.5% | ||
| Q3 24 | 323.0% | -62.1% | ||
| Q2 24 | 5.8% | -78.2% | ||
| Q1 24 | -20.8% | -63.1% |
| Q4 25 | 2.9% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 0.8% | 0.1% | ||
| Q1 25 | 5.1% | 0.2% | ||
| Q4 24 | 7.0% | 0.2% | ||
| Q3 24 | 71.4% | 0.1% | ||
| Q2 24 | 2.5% | 0.4% | ||
| Q1 24 | 5.3% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLFD
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
